CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 11 enrolled
Drug / intervention
Dapagliflozin +1 moredrug
Likely dose
Dapagliflozin 5mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02796170
NCT02796170Phase 4Completed
CompareCT.gov

Inhibition of Urinary Angiotensinogen and the Reduction of Blood Pressure by SGLT2 Inhibition in Patients With Type 2 Diabetes

Tulane University School of Medicine·interventional·Posted Jun 10, 2016·Updated Nov 1, 2022

In Brief

A Phase 4 clinical trial evaluating Dapagliflozin and Placebo for Type 2 Diabetes and Hypertension. Completed, enrolled 11 participants across 1 site.

Detailed Summary

To assess the effect of sodium-glucose cotransporter 2 (SGLT-2) inhibitors on blood pressure and urinary angiotensinogen. This is a cross over study design, where 40 subjects will receive Dapagliflozin for 6 weeks followed by placebo for 6 weeks, or placebo for 6 weeks followed by Dapagliflozin for 6 weeks. In addition there will be an arm of 10 subjects who will receive sulfonylurea in an open label as a comparative to the cross over subjects to assess if the effect of Dapagliflozin may also be in part due to improved glycemic control.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes, Hypertension
CountriesUnited States
CollaboratorsAstraZeneca

Timeline

Phase 4CompletedFinished
20162017201820192020202120222023202420252026
First PostedJun 10, 2016
Enrollment StartMar 1, 2016
Primary CompletionAug 1, 2019
Study CompletionAug 1, 2020
TodayJul 2, 2026
Enrollment to primary: 3.4 yearsPosted 10.1 years ago

Interventions

Dapagliflozindrug

5mg pill taken once daily

Placebodrug

5mg pill taken once daily- placebo of Dapagliflozin